Finasteride

Source: Wikipedia, the free encyclopedia.

Finasteride
Clinical data
Trade namesProscar, Propecia, Finide, others
Other namesMK-906; YM-152; L-652,931; 17β-(N-tert-Butylcarbamoyl)-4-aza-5α-androst-1-en-3-one; N-(1,1-Dimethylethyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
AHFS/Drugs.comMonograph
MedlinePlusa698016
License data
Pregnancy
category
  • AU: X (High risk)
Routes of
administration		By mouth
Drug class5α-Reductase inhibitor
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability65%[5]
Protein binding90%[5]
MetabolismLiver (CYP3A4, ALDH)[5]
Elimination half-lifeAdults: 5–6 hours[5]
Elderly: >8 hours[5]
ExcretionFeces: 57%[5]
Urine: 40%[5]
Identifiers
  • (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
JSmol)
  • O=C(NC(C)(C)C)[C@@H]2[C@]1(CC[C@H]3[C@H]([C@@H]1CC2)CC[C@H]4NC(=O)\C=C/[C@]34C)C
  • InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1 checkY
  • Key:DBEPLOCGEIEOCV-WSBQPABSSA-N checkY
  (verify)

Finasteride, sold under the brand names Proscar and Propecia among others, is a medication used to treat pattern hair loss and benign prostatic hyperplasia (BPH) in men.[6] It can also be used to treat excessive hair growth in women.[7][8] It is usually taken orally but there are topical formulations for patients with hair loss, designed to minimize systemic exposure by acting specifically on hair follicles.[9]

Finasteride is a

5α-reductase inhibitor and therefore an antiandrogen.[10] It works by decreasing the production of dihydrotestosterone (DHT) by about 70%.[6]

In addition to DHT, finasteride also inhibits the production of several anticonvulsant neurosteroids including

THDOC.[11]

Adverse effects from finasteride are rare;[12] however, some men experience sexual dysfunction, depression, and breast enlargement.[13][14] In some men, sexual dysfunction may persist after stopping the medication.[15][16] It may also hide the early symptoms of certain forms of prostate cancer.[14]

Finasteride was patented in 1984 and approved for medical use in 1992.

generic medication.[18] In 2021, it was the 88th most commonly prescribed medication in the United States, with more than 8 million prescriptions.[19][20]

Medical uses

Finasteride has been used for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate[3] and for the treatment of male pattern hair loss (androgenetic alopecia) in men.[4]

Enlarged prostate

Physicians sometimes prescribe finasteride for the treatment of benign prostatic hyperplasia (BPH), informally known as an enlarged prostate.[21] Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start and end of urination, and decreased urinary flow.[22]

The use of the drug showed significant sexual adverse effects such as erectile dysfunction and less sexual desire, in particular when obstructive symptoms due to an enlarged prostate were present.[23]

Scalp hair loss

Finasteride is also used to treat male pattern baldness (androgenic alopecia) in men, a condition that develops in up to 80% of Caucasian men aged 70 and over.[24][4] In the United States, finasteride and minoxidil are the only two FDA approved drugs for the treatment of male pattern hair loss as of 2017.[25] Treatment with finasteride slows further hair loss[26] and provides about 30% improvement in hair loss after six months of treatment, with effectiveness persisting as long as the drug is taken.[14] Taking finasteride leads to a reduction in scalp and serum DHT levels; by lowering scalp levels of DHT, finasteride can maintain or increase the amount of terminal hairs in the anagen phase by inhibiting and sometimes reversing miniaturization of the hair follicle. Finasteride is most effective on the crown but can reduce hair loss in all areas of the scalp.[27][28] Finasteride has also been tested for pattern hair loss in women; however, the results were no better than placebo.[29] Finasteride is less effective in the treatment of scalp hair loss than dutasteride.[30][31]

Prostate cancer

In males aged 55 years old and over finasteride decreases the risk of low-grade prostate cancer but may increase the risk of high-grade prostate cancer and has no effect on overall survival.[32]

A 2010 review found a 25% reduction in the risk of prostate cancer with 5α-reductase inhibitor.[33] A follow-up study of the Medicare claims of participants in a 10-year Prostate Cancer Prevention Trial suggests the reduction in prostate cancer is maintained even after discontinuation of treatment.[34] However, 5α-reductase inhibitors have been found to increase the risk of developing certain rare but aggressive forms of prostate cancer (27% risk increase), although not all studies have observed this.[35] No impact of 5-α-reductase inhibitor on survival has been found in people with prostate cancer.[35]

Excessive hair growth

Finasteride has been found to be effective in the treatment of hirsutism (excessive facial and/or body hair growth) in women. In a study of 89 women with hyperandrogenism due to persistent adrenarche syndrome, finasteride produced a 93% reduction in facial hirsutism and a 73% reduction bodily hirsutism after 2 years of treatment. Other studies using finasteride for hirsutism have also found it to be clearly effective.[7]

Transgender hormone therapy

Finasteride is sometimes used in

transgender women due to its antiandrogenic effects, in combination with a form of estrogen. However, little clinical research of finasteride use for this purpose has been conducted and evidence of safety or efficacy is limited.[8] Moreover, caution has been recommended when prescribing finasteride to transgender women, as finasteride may be associated with side effects such as depression, anxiety, and suicidal ideation, symptoms that are particularly prevalent in the transgender population and in others at high risk already.[36]

Adverse effects

A 2010 Cochrane review of finasteride for BPH found that, in men with a weighted mean age of 62.4, adverse effects are "rare; nevertheless, men taking finasteride are at increased risk for impotence, erectile dysfunction, decreased libido, and ejaculation disorder, versus placebo."[12] As of 2016 fresh evidence suggested such effects, along with disturbed neurosteroid production, may persist after finasteride use is stopped.[37]

Finasteride is contraindicated in pregnancy.[38][39] The Food and Drug Administration advises that donation of blood or plasma be deferred for at least one month after taking the last dose of finasteride.[40]

The FDA has added a warning to 5α-reductase inhibitors concerning an increased risk of high-grade prostate cancer, as the treatment of BPH lowers PSA (prostate-specific antigen), which could mask the development of prostate cancer.[41][42] Although overall incidence of male breast cancer in clinical trials for finasteride 5 mg was not increased, there are post-marketing reports of breast cancer in association with its use, though available evidence does not provide clarity as to whether there is a causative relationship between finasteride and these cancers.[4][43] A 2018 meta-analysis found no higher risk of breast cancer with 5α-reductase inhibitors.[44] Some men develop gynecomastia (breast development or enlargement) following finasteride usage.[45][46][47][48] The risk of gynecomastia with 5α-reductase inhibitors is low at about 1.5%.[49] Depressive symptoms and suicidality have been reported.[50]

Sexual adverse effects

Use of finasteride is associated with an increased risk of sexual dysfunction including erectile dysfunction, decreased libido and ejaculatory dysfunction.[51][13] Sexual adverse effects of finasteride and dutasteride have been linked to lower quality of life and ability to maintain an intimate relationship, and can cause stress in relationships.[52]

The adverse effect profiles of finasteride are somewhat different for its indications of hair loss and BPH.

Finasteride for androgenetic alopecia (hair loss in men)

The most common adverse effects of finasteride taken for hair loss are: decrease in sex drive, erectile dysfunction and decrease in amount of semen.[38]: 17 

In addition, finasteride has been reported in

case reports to cause sexual problems which persist after stopping the medication.[16][15] A 2012 update to the FDA label noted reports of decreased sex drive, problems with ejaculation and difficulty achieving an erection which continued after stopping the medication. The update also referenced reports of testicular pain and "male infertility and/or poor quality of semen."[38]: 17 [14][53][49]

Finasteride for BPH

The most common adverse sexual effects of finasteride for BPH are: trouble getting or keeping an erection, decrease in sex drive, decreased volume of ejaculate and ejaculation disorders.[39]: 16 

A 2010 Cochrane review found that men taking finasteride for BPH (with a mean age of 62.4) are at increased risk for impotence, erectile dysfunction, decreased libido, and ejaculation disorder for the first year of treatment. The rates became indistinguishable from placebo after 2–4 years and these side effects usually got better over time.[12]

Long-term

Finasteride may cause persistent adverse sexual, neurological and physical effects in a subset of men.[15] A 2019 metastudy surveyed the literature on the reversibility of finasteride's side effects. It identified three studies which demonstrated full reversibility of side effects and eleven that describe patients with irreversible adverse events. The findings were most convincing in a retrospective review of about 12,000 patients that 1.4% of the cohort developed persistent ED[15] (ED lasting longer than 90 days post-withdrawal).[54]

Post-finasteride syndrome

Reports of long-term, post-discontinuation adverse effects in some fraction of former finasteride users have led to a proposed post-finasteride syndrome, although some within the medical community question whether there is enough evidence to support a causal relationship between finasteride usage and PFS.[55]

Individuals claiming to experience PFS report sexual, neurological, hormonal and psychological side effects that persist for an extended period after stopping the drug.

decreased ejaculate volume and quality, reduced libido, erectile dysfunction, loss of penile sensitivity, decreased orgasm sensation, dry skin, metabolic changes, muscle and strength loss, gynecomastia, depression, anxiety, panic attacks, insomnia, anhedonia, concentration problems, memory impairment and suicidal ideation.[57] A meta-analysis found significant association between finasteride use and post-discontinuation depression, suicidal ideation, and sexual dysfunction, but the quality of evidence was limited.[58]

The status of PFS as a legitimate and distinct medical pathology remains a subject of debate. A 2019 editorial in The BMJ called post-finasteride syndrome "ill defined and controversial".[59] Some have argued that it has common features with other self-diagnosed "mystery syndromes" such as Morgellons or multiple chemical sensitivity, while others, including some in the biomedical research community, have concluded based on the available evidence that it represents a real and serious condition.[16] There is no known underlying biological mechanism for the proposed syndrome, and its incidence is unclear.[60] A lack of clear diagnostic criteria and the variable reporting fraction in different health-care settings make the problem challenging to evaluate.[57]

As of 2016, Merck was a defendant in approximately 1,370 product liability lawsuits which had been filed by customers alleging they have experienced persistent sexual side effects following cessation of treatment with finasteride.[61] Most cases were settled by 2018 when Merck paid a lump sum of $4.3 million USD to be distributed. As of September 2019, 25 cases remained outstanding in the United States.[62] In 2019, Reuters reported that faulty redactions in court documents revealed allegations from plaintiffs that Merck had known of persistent side effects in their original clinical trials but chose not to disclose them in warning labels.[62]

Overdose

Finasteride has been studied in humans at single doses of up to 400 mg and at continuous dosages of up to 80 mg/day for three months, without adverse effects observed.[4][3][63] There is no specific recommended antidote for finasteride overdose.[4][3]

Interactions

No significant drug interactions have been observed between finasteride and a limited selection of medications.[64]

Pharmacology

Pharmacodynamics

Finasteride is a

prostate gland, skin, and hair follicles.[5][67] As such, finasteride is a type of antiandrogen, or more specifically, an androgen synthesis inhibitor.[68][69] However, some authors do not define finasteride as an "antiandrogen," a term which can refer more specifically to antagonists of the androgen receptor.[70]

Finasteride results in a decrease of circulating DHT levels by about 65–70% with an oral dosage of 5 mg/day and of DHT levels in the prostate gland by up to 80–90% with an oral dosage of 1 or 5 mg/day.

5β-reductase (AKR1D1).[76] However, its affinity for the enzyme is substantially less than for 5α-reductase (an order of magnitude less than for 5α-reductase type I) and hence is unlikely to be of clinical significance.[76]

As of 2012, the tissues in which the different isozymes of 5α-reductase are expressed are not fully clear.

seminal vesicles, testes, epididymides, skin, hair follicles, liver, kidneys, and brain, among others.[67]

By inhibiting 5α-reductase and thus preventing DHT production, finasteride reduces androgen signaling in tissues like the prostate gland and the scalp. In the prostate, this reduces prostate volume, which improves BPH and reduces risk of prostate cancer. Finasteride reduces prostate volume by 20 to 30% in men with benign prostatic hyperplasia.[77] Inhibition of 5α-reductase also reduces epididymal weight, and decreases motility and normal morphology of spermatozoa in the epididymis.[78]

3α-androstanediol (derived from DHT) and allopregnanolone (derived from progesterone) activate the GABAA receptor in the brain; because finasteride prevents the formation of neurosteroids, it functions as a neurosteroidogenesis inhibitor and may contribute to a reduction of GABAA activity. Reduction of GABAA receptor activation by these neurosteroids has been implicated in depression, anxiety, and sexual dysfunction.[79][80][81]

In accordance with finasteride being a potent 5α-reductase inhibitor but a weak inhibitor of 5β-reductase, the medication decreases circulating levels of 5α-reduced steroids like allopregnanolone but does not reduce concentrations of 5β-reduced steroids like pregnanolone.[82][83][84] Pregnanolone acts as a potent GABAA receptor positive allosteric modulator similarly to allopregnanolone.[85]

Pharmacokinetics

The mean

steady-state with 1 mg/day finasteride, mean peak concentrations of finasteride were 9.2 ng/mL (25 nmol/L).[4] Conversely, following a single 5 mg dose of finasteride, mean peak levels of finasteride were 37 ng/mL (99 nmol/L), and plasma concentrations increased by 47–54% following 2.5 weeks of continued daily administration.[3] The volume of distribution of finasteride is 76 L.[5] Its plasma protein binding is 90%.[5] The drug has been found to cross the blood–brain barrier, whereas levels in semen were found to be undetectable.[5]

Finasteride is extensively

terminal half-life of 5 to 6 hours in adult men (18–60 years of age) and a terminal half-life of 8 hours or more in elderly men (more than 70 years of age).[5] It is eliminated as its metabolites 57% in the feces and 40% in the urine.[5]

Chemistry

See also: List of 5α-reductase inhibitors

Finasteride, also known as 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androst-1-en-3-one, is a

lipophilic compound.[64][87]

History

In 1942, James Hamilton observed that prepubertal castration prevents the later development of male pattern baldness in mature men.

deficiency of the 5α-reductase enzyme and male hormone dihydrotestosterone (DHT), which was found to have been the etiology behind abnormalities in male sexual development. Upon maturation, these individuals were observed to have smaller prostates which were underdeveloped, and were also observed to lack incidence of male pattern baldness.[90][91]

In 1975, copies of Imperato-McGinley's presentation were seen by P. Roy Vagelos, who was then serving as Merck's basic-research chief. He was intrigued by the notion that decreased levels of DHT led to the development of smaller prostates. Dr. Vagelos then sought to create a drug which could mimic the condition found in these children to treat older men who had benign prostatic hyperplasia.[92]

Finasteride was developed by Merck under the code name MK-906.

U.S. Food and Drug Administration (FDA) for treatment of BPH, which Merck marketed under the brand name Proscar. Rasmusson and Brooks were awarded IPO's "Inventor of the Year" award in 1993 for their work on finasteride.[94] In 1997, Merck was successful in obtaining FDA approval for a second indication of finasteride (1 mg) for treatment of male pattern hair loss, which was marketed under the brand name Propecia.[95] It was the first 5α-reductase inhibitor to be introduced and was followed by dutasteride in 2001.[96] The first study of finasteride in the treatment of hirsutism in women was published in 1994.[97]

Society and culture

Generic names

Finasteride is the

INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, BANTooltip British Approved Name, and JANTooltip Japanese Accepted Name, while finastéride is its DCFTooltip Dénomination Commune Française.[98][99][100][101] It is also known by its former developmental code names MK-906, YM-152, and L-652,931.[98][99][100][101]

Brand names

Finasteride is marketed primarily under the brand names Propecia, for pattern hair loss, and Proscar, for BPH, both of which are products of

Merck & Co.[101] There is 1 mg of finasteride in Propecia and 5 mg in Proscar. Merck's patent on finasteride for the treatment of BPH expired in June 2006.[102] Merck was awarded a separate patent for the use of finasteride to treat pattern hair loss and it expired in November 2013.[103] Finasteride is also marketed under a variety of other brand names throughout the world.[101]

Athletics

From 2005 to 2009, the

footballer Romário, and ice hockey goaltender José Théodore.[105][106]

Miscellaneous

The U.S. Food and Drug Administration advises that donation of blood or plasma be deferred for at least one month after taking the last dose of finasteride.[107] The UK also has a one-month deferral period.[108]

Research

Preliminary research suggests that topical finasteride may be effective in the treatment of pattern hair loss.[109][110] Topical finasteride, like the oral preparation, reduces serum DHT.[110][109]

DHT may be involved in the cause of

birth control pill in the treatment of acne in women with high androgen levels.[113]

Androgens and estrogens may be involved in the cause of hidradenitis suppurativa (acne inversa).[114][115] Two case series have reported that finasteride is effective in the treatment of hidradenitis suppurativa in girls and women.[113]

Finasteride and other antiandrogens might be useful in the treatment of obsessive–compulsive disorder, but more research is needed.[116]

References

  1. ^ "Propecia 1 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 27 July 2020. Archived from the original on 20 September 2020. Retrieved 29 September 2020.
  2. ^ "Proscar 5mg film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 10 July 2020. Archived from the original on 24 September 2020. Retrieved 29 September 2020.
  3. ^ a b c d e f "Proscar- finasteride tablet, film coated". DailyMed. 15 November 2019. Archived from the original on 26 April 2021. Retrieved 16 September 2020.
  4. ^ a b c d e f g h i j "Propecia- finasteride tablet, film coated". DailyMed. 15 November 2019. Archived from the original on 6 June 2021. Retrieved 16 September 2020.
  5. ^
    ISBN 978-0-7817-6879-5. Archived
    from the original on 10 January 2023. Retrieved 4 December 2017.
  6. ^ a b "Finasteride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 25 August 2018. Retrieved 5 March 2019.
  7. ^
    ISBN 978-3-540-46911-7. Archived
    from the original on 10 January 2023. Retrieved 10 December 2016.
  8. ^
    S2CID 12853220
    .
  9. PMID 34634163
    .
  10. ISBN 9780323084307. Archived
    from the original on 10 January 2023. Retrieved 7 May 2020.
  11. PMID 22835430
    .
  12. ^
    PMID 20927745
    .
  13. ^
    S2CID 85497115
    .
  14. ^
    S2CID 31245042
    .
  15. ^
    S2CID 85497115
    . In studies addressing reversibility, most of these patients have resolution of sexual adverse effects after discontinuation of finasteride, and many have improvement of adverse effects over time with continued finasteride use. However, some studies describe a subset of patients with persistent adverse effects after discontinuation... Level 1 evidence evaluating sexual dysfunction as a primary outcome was available for finasteride.
  16. ^
    S2CID 211064052
    .
  17. ISBN 9783527607495. Archived
    from the original on 10 January 2023. Retrieved 7 May 2020.
  18. ISBN 978-93-5152-459-5. Archived
    from the original on 10 January 2023. Retrieved 4 December 2017.
  19. ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  20. ^ "Finasteride - Drug Usage Statistics". ClinCalc. Archived from the original on 6 February 2020. Retrieved 14 January 2024.
  21. PMID 19707263
    .
  22. ^ "Benign prostate enlargement". nhs.uk. 20 October 2017. Archived from the original on 18 October 2020. Retrieved 20 October 2020.
  23. S2CID 3577324
    .
  24. PMID 29178529
    .
  25. S2CID 46036459
    .
  26. ISBN 978-0-323-26607-9. Archived
    from the original on 10 January 2023. Retrieved 22 October 2016.
  27. S2CID 30008068
    .
  28. S2CID 24833568
    .
  29. PMID 24039457
    .
  30. S2CID 215748750
    .
  31. PMID 30863034
    .
  32. ^ "Finasteride for Prostate Cancer Prevention". National Cancer Institute. 28 August 2013. Archived from the original on 6 February 2020. Retrieved 8 February 2020.
  33. S2CID 22178061
    .
  34. PMID 29534197
    .
  35. ^
    PMID 27672412
    .
  36. S2CID 36236057
    . [...] caution is recommended while prescribing oral finasteride to male-to-female transsexuals, as the drug has been associated with inducing depression, anxiety and suicidal ideation, symptoms that are particularly common in patients with gender dysphoria, who are already at a high risk.[9]
  37. ISBN 9780190678524
    .
  38. ^ a b c "PROPECIA Prescribing Information" (PDF). US Food & Drug Administration / Merck & Co., Inc. Archived (PDF) from the original on 10 February 2017. Retrieved 30 January 2020.
  39. ^ a b "PROSCAR Prescribing Information" (PDF). US Food & Drug Administration / Merck & Co., Inc. Archived (PDF) from the original on 10 February 2017. Retrieved 30 January 2020.
  40. FDA. 28 July 1993. Archived
    from the original on 14 December 2019. Retrieved 30 January 2020.
  41. ^ FDA. Posted 9 June 2011. 5-alpha reductase inhibitors (5-ARIs): Label Change – Increased Risk of Prostate Cancer Archived 18 January 2017 at the Wayback Machine
  42. PMID 20357287
    .
  43. ^ Medicines and Healthcare products Regulatory Agency Drug Safety Update. December 2009 Finasteride: potential risk of male breast cancer Archived 25 October 2014 at the Wayback Machine
  44. PMID 29697934
    .
  45. S2CID 40159424. Archived
    from the original on 4 December 2020. Retrieved 4 July 2019.
  46. S2CID 22938364
    .
  47. PMID 33107592
    .
  48. PMID 20407562
    .
  49. ^
    PMID 27784557
    .
  50. PMID 28456011
    .
  51. PMID 30206635
    .
  52. S2CID 11624116
    .
  53. ^ FDA (11 April 2012). "Questions and Answers: Finasteride Label Changes". US FDA. Archived from the original on 18 August 2014. Retrieved 26 October 2014.
  54. PMID 28289563
    .
  55. S2CID 211064052
    .
  56. ^ Margo J (26 September 2012). "Looking at care with a critical eye". Australian Financial Review. Archived from the original on 14 November 2012.
  57. ^
    S2CID 58569946
    .
  58. S2CID 233028103
    .
  59. S2CID 199518161
    .
  60. S2CID 199518161
    .
  61. ^ Marchalik D (4 February 2017). "Watch for these potential side effects in drug Trump reportedly takes for hair loss". Miami Herald. Archived from the original on 7 December 2018. Retrieved 9 December 2018.
  62. ^ a b "U.S. court let Merck hide secrets about popular drug's risks". Reuters. Archived from the original on 12 February 2020. Retrieved 25 March 2021. these legal briefs filed by plaintiffs' lawyers allege that in revisions to the drug's original 1997 label, Merck understated the number of men who experienced sexual symptoms in clinical trials, and how long those symptoms lasted.
  63. PMID 16719800
    .
  64. ^
    S2CID 71103672
    .
  65. ^
    S2CID 28841145
    .
  66. S2CID 44363501
    .
  67. ^
    PMID 22235201
    .
  68. ISBN 978-90-8686-728-8. Archived
    from the original on 10 January 2023. Retrieved 6 May 2018.
  69. ISBN 978-1-4557-3801-4. Archived
    from the original on 10 January 2023. Retrieved 6 May 2018.
  70. ISBN 978-3-319-46084-0
    . Finasteride is not actually an antiandrogen but a 5α-reductase inhibitor.
  71. S2CID 25793400
    .
  72. PMID 29379733
    .
  73. PMID 7505051
    .
  74. ^
    S2CID 24296644
    .
  75. PMID 12894990
    .
  76. ^
    PMID 19515843
    .
  77. ISBN 978-0-323-08619-6
    .
  78. S2CID 53464391
    .
  79. PMID 16834758
    .
  80. S2CID 24328589. Archived
    from the original on 2 December 2020. Retrieved 26 May 2019.
  81. PMID 22164129
    .
  82. PMID 21176115
    .
  83. PMID 19655698
    .
  84. S2CID 28578077
    .
  85. PMID 15248811
    .
  86. PMID 8117686
    .
  87. S2CID 205563538
    .
  88. doi:10.1002/aja.1000710306
    .
  89. ^ "The extraordinary case of the Guevedoces". BBC News. 20 September 2015. Archived from the original on 13 August 2020. Retrieved 3 September 2018.
  90. S2CID 36427689
    .
  91. ^ Isfort AH, Emerick JE, Paz RA (11 November 2016). "5-Alpha-Reductase Deficiency". WebMD. News & Perspective Drugs & Diseases CME & Education Academy Consult, Drugs & Diseases > Pediatrics: General Medicine. Archived from the original on 6 August 2020. Retrieved 25 October 2014.
  92. ^ Freudenheim M (16 February 1992). "Keeping the Pipeline Filled at Merck". The New York Times. Archived from the original on 14 March 2017. Retrieved 16 February 2017.
  93. ISBN 9780199337149. Archived
    from the original on 10 January 2023. Retrieved 21 June 2020.
  94. ^ "Past Inventor of the Year Award Winners". ipoef.org. Intellectual Property Owners Education Foundation. Archived from the original on 25 June 2020. Retrieved 21 June 2020.
  95. ISBN 978-0-471-37030-7. Archived
    from the original on 10 January 2023. Retrieved 4 December 2017.
  96. ISBN 978-0-12-040538-1. Archived
    from the original on 10 January 2023. Retrieved 4 December 2017.
  97. S2CID 32242838
    .
  98. ^
    ISBN 978-3-88763-075-1
    .
  99. ^
    ISBN 978-94-011-4439-1
    .
  100. ^
    ISBN 978-1-4822-8215-3. Archived
    from the original on 10 January 2023. Retrieved 6 May 2018.
  101. ^ a b c d "Finasteride". Archived from the original on 8 April 2019. Retrieved 6 December 2017.
  102. ^ "Primary Patent Expirations for Selected High Revenue Drugs". RxNews. Prescription Solutions. Archived from the original on 21 March 2008.
  103. ^ FDA. "Patent Expiration for Propecia". Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Archived from the original on 26 October 2016. Retrieved 17 August 2007.
  104. ^ Sandomir R (19 January 2006). "Skin Deep; Fighting Baldness, and Now an Olympic Ban". The New York Times. Archived from the original on 4 December 2017. Retrieved 2 May 2010.
  105. ^ a b Staff (28 October 2008). "WADA removes Finasteride from ban list". The Australian.
  106. ^ Staff (9 October 2008). "WADA takes Romario's drug off banned list". Sydney Morning Herald. Archived from the original on 25 September 2015. Retrieved 25 October 2014.
  107. FDA. 28 July 1993. Archived
    (PDF) from the original on 8 February 2017. Retrieved 4 February 2017.
  108. ^ "Anti-Androgens - Joint United Kingdom Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee". www.transfusionguidelines.org. 1 June 2007. Archived from the original on 12 November 2020. Retrieved 13 May 2020.
  109. ^
    PMID 29601622
    .
  110. ^
    S2CID 209331373
    .
  111. ISBN 978-1-118-23277-4. Archived
    from the original on 10 January 2023. Retrieved 24 March 2019.
  112. ^
    S2CID 8325257
    .
  113. ^
    S2CID 58555908
    .
  114. PMID 19293006
    .
  115. PMID 28128074
    .
  116. S2CID 208956450
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Finasteride&oldid=1218261933"